France's Vetoquinol Q1 sales fall 4.3% on FX impact

Vetoquinol SA

28/04/2026 17:00

Overview

France animal health firm's Q1 sales down 4.3% on reported basis, nearly flat at constant FX

Sales decline mainly due to negative FX impact and product line simplification program

Excluding FX and product line effects, sales rose 1.2% yr/yr

Outlook

Vetoquinol says 2026 will be a transition year with a slowdown in product line simplification

Company preparing for launch of new Essentials products in 2027

Company notes highly unstable geopolitical environment could impact business activity

Result Drivers

NEGATIVE FX IMPACT - Co said historically high negative currency effects, especially in the U.S. and India, reduced reported sales by €5.2 mln

PRODUCT LINE SIMPLIFICATION - Ongoing program to simplify complementary product lines reduced sales by €1.7 mln

U.S. SALES REBOUND - Sales in the U.S. rose 15.6% at constant exchange rates, confirming a rebound in the region

Company press release: ID:nBw3QcGBwa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
EUR 125 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Vetoquinol SA is €86.50, about 8.1% above its April 27 closing price of €80.00

The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)